Influence of Loading Dose Of Atorvastatin on the Risk of Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction

Aim      This retrospective cohort study focused on evaluating the incidence of contrast-induced nephropathy (CIN) associated with administration of an atorvastatin loading dose (80 mg) prior to invasive coronary angiography (CAG) in patients with ST-segment elevation myocardial infarction (STEMI).

Material and methods  This retrospective cohort study included 386 patients with STEMI. The patients were divided into two groups: intervention group (n=118) and control group (n=268). Patients in the intervention group, at the stage of admission to the catheterization laboratory, were administered a loading dose of atorvastatin (80 mg, p.o.) immediately before access (introducer placement). The endpoints were development of CIN, which was determined by increased serum creatinine 48 h following the intervention by at least 25% (or 44 µmol/l) of baseline value. In addition, in-hospital mortality and incidence of CIN resolution were assessed. To adjust the groups for dissimilar characteristics, a “pseudorandomization” method was used by comparing propensity scores.

Results The incidence of CIN was significantly lower in the intervention group than in the control group (10.5 % vs. 24.4 %; p=0.016) with the odds for the CIN development lower than in the control group (odds ratio (OR) 0.36; 95 % confidence interval (CI), 0.16–0.85). Creatinine concentrations returned to the baseline value in 7 days more frequently than in the control group (66.3 % vs. 50.6 %, respectively; OR, 1.92; 95 % CI, 1.04–3.56; p=0.037). In-hospital mortality was higher in the control group but did not differ significantly between the groups.

Conclusion      ~Administration of atorvastatin 80 mg to STEMI patients immediately before CAG was associated with a reduced risk of CIN and a higher likelihood of serum creatinine returning to the values at admission by day 7. 

1. Shams E, Mayrovitz HN. Contrast-Induced Nephropathy: A Review of Mechanisms and Risks. Cureus. 2021;13(5):e14842. DOI: 10.7759/cureus.14842

2. Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy. Life Sciences. 2020;259:118379. DOI: 10.1016/j.lfs.2020.118379

3. Hossain M, Costanzo E, Cosentino J, Patel C, Qaisar H, Singh V et al. Contrast-Induced nephropathy: Pathophysiology, risk factors, and prevention. Saudi Journal of Kidney Diseases and Transplantation. 2018;29(1):1–9. DOI: 10.4103/1319-2442.225199

4. Demchuk O.V., Sukmanova I.A., Ponomarenko I.V., Elykomov V.A. Contrast-induced nephropathy in patients with acute coronary syndrome: clinical significance, diagnosis, prophylaxis. Cardiovascular Therapy and Prevention. 2020;19(2):82–8. DOI: 10.15829/1728-8800-2019-2255

5. Mezhonov E.M., Vakulchik K.A., Vyalkina Yu.A., Shalaev S.V. Acute renal injury in patients with ST-segment elevation myocardial infarction of the electrocardiogram. Emergency cardiology. 2017;3:5–12.

6. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders H-J. Acute kidney injury. Nature Reviews Disease Primers. 2021;7(1):52. DOI: 10.1038/s41572-021-00284-z

7. Nijssen EC, Rennenberg R, Nelemans P, van Ommen V, Wildberger JE. Post-Contrast Acute Kidney Injury and Intravenous Prophylactic Hydration: An Update. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2021;193(2):151–9. DOI: 10.1055/a-1248-9178

8. Andò G, Cortese B, Russo F, Rothenbühler M, Frigoli E, Gargiulo G et al. Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology. 2017;69(21):2592–603. DOI: 10.1016/j.jacc.2017.02.070

9. Yavelov I.S., Zhatkina M.V., Drapkina O.M., Gorshkov A.Yu., Myasnikova N.O. High Doses of Statins before Percutaneous Coronary Intervention: whether There Are Reasons to Use? Rational Pharmacotherapy in Cardiology. 2017;13(4):532–40. DOI: 10.20996/1819-6446-2017-13-4-532-540

10. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. New England Journal of Medicine. 2019;380(22):2146–55. DOI: 10.1056/NEJMra1805256

11. Giacoppo D, Gargiulo G, Buccheri S, Aruta P, Byrne RA, Cassese S et al. Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients. Circulation: Cardiovascular Interventions. 2017;10(5):e004383. DOI: 10.1161/CIRCINTERVENTIONS.116.004383

12. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–77. DOI: 10.1093/eurheartj/ehx393

13. Kobalava Zh.D., Villevalde S.V., Efremovtseva M.A. Cardiorenal interaction in decompensated chronic heart failure. Rational Pharmacotherapy in Cardiology. 2016;12(2):138–46. DOI: 10.20996/1819-6446-2016-12-2-138-146

14. Zhou Y-L, Chen L-Q, Du X-G. Efficacy of short-term moderate or high-dose statin therapy for the prevention of contrast-induced nephropathy in high-risk patients with chronic kidney disease: systematic review and meta-analysis. Clinics. 2021;76:e1876. DOI: 10.6061/clinics/2021/e1876

15. Sun Y-Y, Liu L-Y, Sun T, Wu M-Y, Ma F-Z. Prophylactic atorvastatin prior to intra-arterial administration of iodinated contrast media for prevention of contrast-induced acute kidney injury: A meta-analysis of randomized trial data. Clinical Nephrology. 2019;92(3):123–30. DOI: 10.5414/CN109497

16. Li W, Fu X, Wang Y, Li X, Yang Z, Wang X et al. Beneficial Effects of High-Dose Atorvastatin Pretreatment on Renal Function in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention. Cardiology. 2012;122(3):195–202. DOI: 10.1159/000339472

17. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome: Results from the PRATOACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). Journal of the American College of Cardiology. 2014;63(1):71–9. DOI: 10.1016/j.jacc.2013.04.105